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Background: Human immunodeficiency virus (HIV) and methamphetamine use commonly 
affect neurocognitive (NC) functioning. We evaluated the relationships between NC function-
ing and two fibroblast growth factors (FGFs) in volunteers who differed in HIV serostatus and 
methamphetamine dependence (MAD).
Methods: A total of 100 volunteers were categorized into four groups based on HIV serostatus 
and MAD in the prior year. FGF-1 and FGF-2 were measured in cerebrospinal fluid by enzyme-
linked immunosorbent assays along with two reference biomarkers (monocyte chemotactic 
protein [MCP]-1 and neopterin). Comprehensive NC testing was summarized by global and 
domain impairment ratings.
Results: Sixty-three volunteers were HIV+ and 59 had a history of MAD. FGF-1, FGF-2, and both 
reference biomarkers differed by HIV and MAD status. For example, FGF-1 levels were lower in 
subjects who had either HIV or MAD than in HIV– and MAD– controls (P=0.003). Multi variable 
regression identified that global NC impairment was associated with an interaction between FGF-1 
and FGF-2 (model R2=0.09, P=0.01): higher FGF-2 levels were only associated with neurocogni-
tive impairment among subjects who had lower FGF-1 levels. Including other covariates in the 
model (including antidepressant use) strengthened the model (model R2=0.18, P=0.004) but did 
not weaken the association with FGF-1 and FGF-2. Lower FGF-1 levels were associated with 
impairment in five of seven cognitive domains, more than FGF-2, MCP-1, or neopterin.
Conclusion: These findings provide in vivo support that HIV and MAD alter expression of 
FGFs, which may contribute to the NC abnormalities associated with these conditions. These 
cross-sectional findings cannot establish causality and the therapeutic benefits of recombinant 
FGF-1 need to be investigated.
Keywords: biomarker, cerebrospinal fluid, fibroblast growth factor, HIV, methamphetamine, 
HIV-associated neurocognitive disorders, HAND, neurocognitive impairment
Background
Human immunodeficiency virus (HIV) infects the central nervous system (CNS) and can 
cause HIV-associated neurocognitive disorders that range in severity from asymptomatic 
neurocognitive impairment (ANI) to HIV-associated dementia (HAD).1 HIV specifically 
infects perivascular macrophages, microglia, and, to a limited extent, astrocytes and this 
is followed by the release of proinflammatory cytokines and viral proteins that can lead to 
reversible and sometimes irreversible neuronal injury.2 These neuropathological changes 
can be exacerbated by the use of drugs of abuse, such as methamphetamine (MA).3 
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While immune and glial activation play influential roles in 
HIV pathogenesis in the CNS, dysregulation of neuro protective 
mechanisms may also contribute.
Fibroblast growth factors (FGFs) are expressed in the 
brain and are involved in brain development and neuropro-
tection. The FGF family has diverse physiologic functions, 
including cell differentiation, migration, and survival. In the 
brain, FGF-1 is primarily produced by neurons, promotes 
neuronal survival, and may protect calbindin-immunoreactive 
interneurons from the neurotoxic effects of HIV-gp120.4–7 
FGF-2 is produced by astrocytes as well as neurons and 
sustains endothelial cell fitness and blood–brain barrier 
(BBB) homeostasis. FGF-2 may also have neuroprotective 
properties, for example, it seems to protect against ischemic 
challenges.8–13 Of potential concern for HIV disease-related 
pathology, FGF-2 may upregulate the HIV co-receptor, 
CXCR4, in a dose-dependent manner.6 FGF-2 may also 
influence neural precursor cells. Of potential significance, 
FGF administration could be a new therapeutic modality for 
HIV-associated neurocognitive disorders: recombinant FGFs 
have been synthesized and are being evaluated in such diverse 
conditions as vascular disease,14 chronic kidney disease,15 
and wound healing.16
Since cerebrospinal fluid (CSF) is in direct contact with the 
brain, concentrations of FGFs in CSF may reflect the expres-
sion of these proteins in neurons and glia. Few published 
studies have reported concentrations of FGFs in the CSF of 
humans. One early study reported FGF-like activity in the CSF 
of subjects who suffered from a traumatic brain injury.17 Two 
other studies identified that FGF-2 was elevated in the CSF of 
subjects with either amyotrophic lateral sclerosis (ALS)18 or 
moyamoya.19 A recent study showed a similar elevation of 
FGF-1 in the CSF of patients with Alzheimer’s disease.20
The objective of this analysis was to evaluate the relationships 
between two FGFs and neurocognitive (NC) disease in subjects 
who differed by HIV and MA characteristics. To accomplish 
this, we assessed volunteers with a standardized  neuromedical 
examination, lumbar puncture, and a comprehensive battery of 
NC tests. We also measured two reference biomarkers (mono-
cyte chemotactic protein [MCP]-1 and neopterin) that have been 
implicated in HIV-associated NC disease.21,22
Methods
Participants were 100 volunteers who enrolled in a US 
National Institute on Drug Abuse-funded program (P01 
DA12065) at University of California San Diego (UCSD)’s 
HIV Neurobehavioral Research Program (HNRP). Subjects 
were categorized into four groups based on the presence or 
absence of HIV disease and methamphetamine dependence 
(MAD) within the prior year. MAD was diagnosed using 
the Composite International Diagnostic Interview. In the 
parent project, subjects were excluded if they had used MA 
within 2 weeks or if they had a history of psychotic disorders, 
neurological disorders (eg, epilepsy), head injury, or loss 
of consciousness of $30 minutes, or other substance use 
disorders (except cannabis). Volunteers were selected for 
this subanalysis if they were hepatitis C virus (HCV) sero-
negative, successfully underwent lumbar puncture, and had 
sufficient CSF in storage at −80°C to perform the biomarker 
assays of interest. This study was reviewed by and received 
ethics approval from the UCSD Human Research Protections 
Program (http://irb.ucsd.edu/). All subjects provided written 
informed consent prior to enrollment.
Participants underwent a standardized comprehensive NC 
assessment.3 Seven cognitive abilities that may be affected 
by HIV and MA were tested: verbal fluency; attention and 
working memory; speed of information processing; learn-
ing; delayed recall; executive functions; and motor skills. 
A global deficit score (GDS) summarized participants’ overall 
performance on the NC tests, raw performance on which was 
adjusted for age, education, sex, and race/ethnicity.3 This 
continuous metric ranged between 0 and 5. A score of 0.5 
is consistent with definite impairment, with higher scores 
indicating increasingly severe NC impairment.
HIV infection was diagnosed by standard clinical anti-
body detection. HIV RNA were measured in plasma and 
CSF using an assay that had a nominal detection limit of 
50 copies/mL (c/mL). CD4+ T-cell counts were measured in 
blood by routine clinical flow cytometry. Absence of recent 
recreational drug use was confirmed by testing the urine 
of each subject with an on-site screening test for common 
recreational drugs (including amphetamines, cocaine, bar-
biturates, cannabinoids, opiates, benzodiazepines, and phen-
cyclidines). CSF was collected by routine lumbar puncture 
using a 22-gauge atraumatic needle.
FGF-1 and FGF-2 were measured by commercial 
enzyme-linked immunosorbent assays (ELISA) (R&D 
 Systems, Minneapolis, MN, USA). The lower limits of detec-
tion were 5.7 pg/mL for FGF-1 (DFB00b) and 3.0 pg/mL for 
FGF-2 (DFB50). MCP-1 was measured using a bead-based 
suspension immunoassay (Millipore, Billerica, MA, USA; 
lower limit of detection 3.2 pg/mL). Neopterin was measured 
using a commercial ELISA (GenWay Biotech, San Diego, 
CA, USA; Cat 40-371-25012; limit of detection 0.7 nmol/L). 
All assays were performed in duplicate. All coefficients of 
variation between duplicate wells were below 20%.
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Statistical analysis
Data were analyzed using JMP software (SAS Institute, Cary, 
NC, USA). Values of some variables, including all four bio-
markers, were transformed to improve the symmetry of their 
distribution. When assumptions were met, parametric tests 
(Student’s t-tests, Pearson’s correlation coefficient) were used. 
When assumptions were not met, nonparametric tests were 
used. Analysis of variance was used to analyze differences 
between more than two groups. Multivariable analyses were 
performed in two stages. In the first stage, stepwise linear 
regression was performed using HIV status, MAD group, 
FGF-1 and FGF-2 along with first-order interactions as can-
didate covariates. Second-stage modeling added demographic 
and disease characteristics (eg, HIV RNA levels) as well as 
levels of the two reference biomarkers (MCP-1 and neopterin) 
as candidate covariates. Antidepressant use was included 
as a candidate covariate in second-stage modeling since it 
has been linked to FGF expression.23,24 In both stages, the 
Akaike Information Criterion was used to determine relative 
goodness-of-fit. When interactions were identified, recursive 
partitioning was used to visualize the nature of the interaction 
using 10% of the sample as the minimum split size.
Results
Subject characteristics
Subjects were mostly middle-aged (mean 39.5 years), White 
(68%) men (95%) with some college education (mean 
12.9 years). Sixty-three were HIV+ and 59 had a history of 
MAD. The four groups defined by HIV and MAD status dif-
fered in sex (P=0.04) and antidepressant use (P=0.002) and 
tended to differ in education (P=0.08) but did not differ in 
other demographic characteristics or by global NC impair-
ment. By design, all subjects were HCV seronegative. The 
two HIV+ groups did not differ in their HIV disease charac-
teristics, except that more MAD+ subjects were taking failing 
antiretroviral therapy (ART) (ie, they were taking ART but 
had HIV RNA levels .50 c/mL). Subject characteristics are 
summarized in Table 1.
FGFs, MCP-1, and neopterin
FGF-1 in CSF ranged from 5.7 to 1,532 pg/mL (median 40.2, 
interquartile range [IQR] 26.3–83.3). FGF-2 in CSF ranged 
from 3.2 to 43.5 pg/mL (median 7.7, IQR 6–12.4). MCP-1 
in CSF ranged from 216.6 to 2,557 pg/mL (median 507.8, 
IQR 417.7–693.2) and neopterin in CSF ranged from 2.4 to 
59.7 nmol/mL (median 7.5, IQR 5.4–12.2).
FGF-1 and FGF-2 correlated with each other (ρ=−0.41, 
P,0.0001). Each correlated with MCP-1 (FGF-1: ρ=0.33, 
P=0.0009; FGF-2: ρ=−0.54, P,0.0001) but neither strongly 
correlated with neopterin (FGF-1: ρ=0.04, P=0.68; FGF-2: 
ρ=−0.16, P=0.12).
All four biomarkers differed by HIV or MAD status 
(Table 1) with differing patterns of association. FGF-1 was 
much higher in control subjects (d=1.2, P=0.02 for the com-
parison between HIV–MAD– vs all others) but did not differ 
between the three other groups (P=0.67). FGF-2 was higher 
in subjects who had a history of MAD (d=0.80, P,0.0001) 
but did not differ by HIV status (P=0.34). MCP-1 was lower 
in the HIV–MAD+ group (d=0.80, P=0.0002) but did not 
differ among the other 3 groups (P=0.29). HIV+ subjects 
had higher neopterin levels (d=0.70, P=0.0004) but MAD+ 
subjects trended toward lower levels (d=0.37, P=0.09). Since 
the four HIV/MAD groups differed by sex, antidepressant 
use, and education (Table 1), we adjusted for these covariates 
in multivariable linear regression models predicting each 
biomarker. The observed associations between HIV, MAD, 
and each biomarker did not significantly change after these 
adjustments.
Among HIV+ individuals, several biomarkers tended 
to differ based on plasma HIV RNA suppression but none 
of the comparisons reached statistical significance (mean 
MCP-1 567.1 pg/mL when plasma HIV RNA undetectable 
vs 713.8 pg/mL when detectable, P=0.12; mean neopterin 
9.7 nmol/mL when plasma HIV RNA undetectable vs 12.7 
when detectable, P=0.17; mean FGF-2 11.2 pg/mL when 
plasma HIV RNA undetectable vs 8.8 when detectable, 
P=0.16). FGF-1 in CSF was not associated with either HIV 
RNA levels or ART use. None of the biomarkers correlated 
with current or nadir CD4+ T-cell counts.
Associations with global nC impairment
In this subgroup (n=100) of the larger cohort25 that met the 
selection criteria, global neurocognitive impairment (NCI) 
was not statistically significantly associated with either 
HIV seropositivity (relative risk 1.25, P=0.23) or history 
of MAD (relative risk 1.13, P=0.65). Global NCI was also 
not associated with demographic characteristics, although it 
trended toward an association with White ethnicity (77.8% 
of impaired subjects were White vs 59.7% of unimpaired 
subjects, P=0.11).
Global NCI was associated with lower FGF-1 levels 
in CSF (d=0.47, P=0.003) but not with levels of FGF-2 
(P=0.38), MCP-1 (P=0.22), or neopterin (P=0.41). First-
stage multivariable modeling identified that global NCI was 
associated with an interaction between FGF-1 and FGF-2 
(model R2=0.09, P=0.01). Recursive partitioning identified 
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Table 1 Demographic and disease characteristics of research subjects, stratified by neurocognitive impairment status
Groups
HIV-MAD- (N=12) HIV-MAD+ (N=25) HIV+MAD- (N=29) HIV+MAD+ (N=34) P-value
Age (years, mean ± SD) 42.3±9.4 38.7±9.4 39.1±8.6 37.1±7.3 0.33
Sex (women, %) 25.0 0.0 3.4 2.9 0.04
Ethnicity (White, %) 50.0 60.0 71.4 67.6 0.57
Education (years, mean ± SD) 12.1±2.1 12.4±2.0 12.9±1.4 13.5±2.1 0.08
HCV serostatus (positive, %) 0.0 0.0 0.0 0.0 –
Global neurocognitive impairment (%) 16.7 27.6 44.0 20.6 0.19
Antidepressant use (%) 0.0 20.0 41.4 47.1 0.002
FGF-1, CSF (mean ± SD, pg/mL) 418.0±497 47.1±35.5 91.6±131.8 92.4±151.4 0.003
FGF-2, CSF (mean ± SD, pg/mL) 6.8±1.2 12.2±5.5 7.8±3.2 11.2±7.5 0.001
MCP-1, CSF (mean ± SD, pg/mL) 706.2±347.0 443.2±142.7 700.9±307.7 621.3±421.9 0.002
Neopterin, CSF (mean ± SD, pg/mL) 8.1±6.6 6.6±2.9 13.9±12.5 10.3±7.2 0.005
Current CD4+ T-cell count (mean ± SD, μl−1) nA nA 530±269 481±279 0.48
nadir CD4+ T-cell count (mean ± SD, /μl−1) nA nA 263±225 311±216 0.39
AIDS (with diagnosis, %) nA nA 51.7 32.4 0.12
Current ART use (%) nA nA 65.5 44.1 0.13
Among those taking ART
 CPe (mean ± SD) nA nA 7.3±2.5 7.7±2.2 0.67
 HIV RNA, plasma (% ,50 c/ml) nA nA 73.7 26.7 0.01
 HIV RNA, CSF (% ,50 c/mL, n=60) nA nA 94.4 57.1 0.03
Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; CPE, CNS penetration score; CSF, cerebrospinal fluid; FGF, fibroblast growth 
factor; HCV, hepatitis C virus; HIV, human immunodeficiency virus; MAD, methamphetamine dependence; MCP, monocyte chemotactic protein; NA, not applicable; 
RNA, ribonucleic acid; SD, standard deviation.
the nature of the interaction: higher FGF-2 levels were only 
associated with NCI among those with lower FGF-1 levels 
(Figure 1A). The second-stage modeling identified additional 
covariates that strengthened the model but the interaction 
between FGF-1 and FGF-2 was not weakened by their inclu-
sion (model R2=0.18, P=0.004). Covariates that explained 
additional variance in global NCI included HIV serostatus 
(parameter estimate P=0.03) and an interaction between 
FGF-1 and neopterin (parameter estimate P=0.02). Recur-
sive partitioning identified that the nature of the interaction 
was similar to the one between FGF-1 and FGF-2: higher 
neopterin levels were associated with NCI only among those 
with lower FGF-1 levels (Figure 1B).
Among people living with HIV disease, global NCI 
trended toward an association with lower FGF-1 levels 
(P=0.109) but not with demographic, disease, or treatment 
characteristics. The size of the HIV+ sample (n=63) limited 
multivariable models. In first-stage models, only the interac-
tion between FGF-1 and FGF-2 entered the model of global 
NCI (R2=0.09, P=0.01). In the second-stage of modeling that 
accounted for HIV and ART characteristics, no additional 
covariates entered the model.
Among the 37 subjects who had undetectable HIV RNA 
levels in plasma, global NCI was associated with older 
age (mean 43.3 years vs 38.7 years, P=0.03) and trended 
toward associations with lower FGF-1 levels (P=0.106) 
and lower CNS penetration score values (mean 5.7 vs 8.5, 
d=1.0, P=0.06) but not with other demographic, disease, or 
treatment characteristics. Considering the small size of the 
subgroup with suppressed plasma HIV RNA in this analysis, 
no multivariable modeling was performed.
Associations with domain nCI
The patterns of associations of the two FGFs and the two refer-
ence biomarkers with impairment in specific cognitive domains 
differed. Lower levels of FGF-1 at least trended toward asso-
ciation with impairment in the largest number of domains: 
learning (d=0.37, P=0.04), working memory (d=0.36, P=0.07), 
recall (d=0.33, P=0.10), speed of information processing 
(d=0.40, P=0.12), and motor functioning (d=0.34, P=0.12). 
Higher FGF-2 levels trended toward association with speed 
of information processing impairment (d=0.69, P=0.11) while 
lower levels were associated with verbal functioning impair-
ment (d=0.40, P=0.05). Higher MCP-1 levels were associated 
with motor impairment (d=0.62, P=0.03) while lower levels 
were associated with speed of information processing impair-
ment (d=0.84, P=0.007). Neopterin was not associated with 
impairment in any single domain. The domain that had the 
strongest association for neopterin was motor functioning: 
the association between motor impairment and neopterin had 
a small effect size (d=0.30, P=0.19).
The domains most commonly correlated with these four 
biomarkers were motor functioning and speed of informa-
tion processing. Multivariable analysis identified that motor 
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impairment was associated with HIV disease, MAD, and 
levels of three of the four biomarkers (FGF-1, FGF-2, 
and MCP-1) (model R2=0.41, P,0.0001). This model 
included an interaction between MAD and FGF-1 that was 
visualized using recursive partitioning (Figure 1C). Speed 
of information processing impairment was associated only 
with lower MCP-1 levels (model R2=0.10, P=0.03), although 
modeling was limited by the small number of subjects with 
speed of information processing impairment (n=6).
Discussion
Our analysis is the largest to date to measure FGFs in CSF 
from adults living with HIV disease and the first to compare 
them to MAD. A smaller published report identified lower 
FGF-2 concentrations in CSF collected from 19 individu-
als with HIV-associated minor NC disorder compared with 
HIV seronegative controls.26 Our primary findings were that 
1) lower FGF-1 concentrations in CSF were associated with 
HIV disease, MAD, and NCI and 2) higher concentrations 
of FGF-2 were associated with MAD (but not with HIV) 
and influenced the relationship between FGF-1 and NC 
functioning.
These findings provide in vivo support for the neuro-
protective properties of FGF-1. Such a role was previously 
proposed by investigators in our group based on the observa-
tion that neurodegeneration was associated with a reduction 
in the FGF-1 expression in brain tissue from individuals 
with antemortem NCI and postmortem HIV encephalitis.4 
Our group also showed that FGF-1 was protective against 
neurotoxicity due to the HIV envelope protein gp120 in 
primary human neuronal cultures.4 Using transgenic mice 
expressing human FGF-1, we also demonstrated a similar 
benefit that might be due to inactivation of glycogen synthase 
kinase (GSK) 3β.27
In contrast, FGF-2 appears to be predominantly associa-
ted with neurologic injury since higher FGF-2 concentra-
tions in CSF were associated with global NCI. The possible 
deleterious effects of FGF-2 are consistent with reports that 
FGF-2 mRNA levels are elevated in the frontal cortex of 
cognitively impaired acquired immune deficiency syndrome 
(AIDS) patients28 and that FGF-2 may contribute to neuronal 
damage in multiple sclerosis.29 An alternative explanation for 
our findings is that the reported neuroprotective effects of 
FGF-230,31 are either inadequate in the presence of chronic 
disease or are influenced by other factors, which is supported 
by the observed interaction between FGF-2 and FGF-1. The 
strong correlation between FGF-2 and MCP-1 raises concerns 
about colinearity in multivariable analyses. Longitudinal data, 
particularly following a therapeutic intervention, might better 
discern the distinct effects of FGF-2.
Analyses of individual cognitive domains also support 
that FGF-1 and FGF-2 may lead to injury of different neu-
ral circuits. Multiple biomarkers, including FGF-1, were 
associated with motor functioning and speed of information 
processing but, among our small panel of biomarkers, only 
FGF-1 was associated with learning and memory impair-
ment. Dopaminergic systems subserve these functions and 
can be adversely affected by either HIV or MAD. While 
other circuits support learning and memory, support for 
the relationship between FGF-1 and dopaminergic systems 
is present for the subjects included in this analysis: lower 
FGF-1 levels correlated with higher levels of homovanillic 
acid, a catecholamine metabolite, in CSF (r=−0.23, P=0.04) 
and higher dopamine-to-homovanillic acid ratios (r =−0.27, 
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P=0.01; data not shown). The domain analysis also identified 
that FGF-2 and MCP-1 may be associated with cognitive 
abilities differently; higher levels were associated with 
impairment in one domain while lower levels were associ-
ated with impairment in another. While these findings could 
be due to type I statistical error, they could also explain why 
the strength of associations with MCP-1, for instance, has 
varied from study to study (ie, the findings depend on the 
prevalence of impaired domains in each cohort).
An important limitation of our project is that we only 
measured FGFs in CSF, not in blood. While CSF likely pro-
vides a better window into CNS events than blood, we could 
have more confidently ascribed the production of FGFs to 
glia and neurons if we had shown the absence of significant 
associations with FGF concentrations in blood. Instead, we 
must consider the possibility that our observations are due 
to events outside the CNS since blood–CSF barrier and BBB 
permeability perturbations might have allowed diffusion of 
blood-derived FGFs into CSF. This might be particularly true 
since MA can alter BBB permeability by modulating tight 
junction expression to decrease transendothelial resistance 
as well as enhanced transendothelial migration of immune 
cells.32 Another important limitation is the cross-sectional 
design of our analyses. Such designs are inherently limited 
in their ability to account for bias, particularly bias due to 
inter-individual differences in time-linked factors such as 
HIV disease trajectory or the density of MA use over time. 
Cross-sectional designs are also very limited in their ability 
to determine causality. This analysis also included relatively 
few HIV+ subjects who were taking suppressive antiretroviral 
therapy. Thus, while the 2×2 design enables inferences about 
the associations between HIV, MAD, and FGFs, the findings 
may not generalize well to effectively treated HIV+ patients 
in the clinic.
These findings may be particularly important since 
human recombinant FGF-1 is being evaluated as a clini-
cal treatment, albeit for other indications (coronary artery 
disease [NCT00117936] and peripheral vascular disease 
[NCT00424866]). Even if a future clinical trial demonstrates 
that human recombinant FGF-1 safely and effectively treats 
HIV- or MA-associated NCI, its parenteral administration 
will limit its use. Orally administered drugs would be more 
clinically useful. If our findings are due, in part, to modulation 
of downstream molecules such as GSK3β, then modulators of 
signaling pathways, such as oral lithium, might also protect 
the CNS from HIV-related neurotoxicity. Consistent with 
this, lithium has evidence of in vitro and in vivo benefits in 
HIV disease.27
In conclusion, we have shown that HIV and MAD are 
each associated with reductions in FGF-1 levels in CSF and 
these reductions were associated with worse NC functioning. 
Further studies are required to confirm these findings and to 
determine if these associations are also present in effectively 
treated people living with HIV disease.
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